Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria : A Systematic Review and Meta-Analysis

Thumbnail Image
antibiotics-13-01048-v3.pdf (1.71 MB)
Identifiers
URI: https://hdl.handle.net/10641/7659
ISSN: 2079-6382
DOI: 10.3390/antibiotics13111048

Publication date

2024-11

Start date of the public exhibition period

End date of the public exhibition period

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Share
Export

Research Projects

Organizational Units

Journal Issue

Doctoral program

Description

Publisher Copyright: © 2024 by the authors.

Keywords

Acinetobacter baumannii, Gram-negative bacteria, ICU, MDR, cefiderocol, critically ill, severe infections, Microbiology, Biochemistry, General Pharmacology, Toxicology and Pharmaceutics, Microbiology (medical), Infectious Diseases, Pharmacology (medical), SDG 3 - Good Health and Well-being, Journal Article, Review, Yes, yes

Citation

Risco-Risco, C, Henriquez-Camacho, C, Herrera-Rueda, M, Barberán, J & Andaluz-Ojeda, D 2024, 'Cefiderocol Versus Best Available Therapy in the Treatment of Critically Ill Patients with Severe Infections Due to Resistant Gram-Negative Bacteria : A Systematic Review and Meta-Analysis', Antibiotics, vol. 13, no. 11, 1048. https://doi.org/10.3390/antibiotics13111048

Collections

FACULTAD DE MEDICINA